Immune thrombocytopenia is an autoimmune disorder characterized by antibody-mediated platelet destruction. A protein tyrosine phosphatase (PTPN22) present in lymphocytes is an important negative regulator of signal transduction for the T-cell receptor-MHC complex and has been associated with autoimmune disorders that produce autoantibodies. The present study investigated the frequency of the 1858C>T single-nucleotide polymorphism (SNP) in the PTPN22 gene in idiopathic thrombocytopenic purpura (ITP) patients. This case series study included 50 children with ITP, 24 acute and 26 chronic cases, and 50 normal children as a control group. All were subjected to clinical history and laboratory investigations including complete blood count, genotyping of PTPN22 1858C/T SNP by polymerase chain reaction-restriction fragment length polymorphism and platelet antibodies using platelets suspension immunofluorescence test for the cases. Thirteen patients (26%) were positive for the PTPN22 1858C>T SNP. Three patients were homozygous for the mutation and 10 were heterozygous. Comparison of the 26% of the ITP patients who were positive for the PTPN22 1858C>T mutation with the 6% positive in the control group yielded a P value of 0.006. Antiplatelet antibodies were detected in five patients (20.8%) with acute ITP and in three patients (11.5%) with chronic ITP; no significant association between the presence of PTPN22 1858C>T mutation and the presence of antiplatelet antibodies was detected. The prevalence of PTPN22 gene mutation was higher in ITP patients, thus it may be considered as a genetic risk factor in the development of ITP in Egyptian children. Blood Coagul Fibrinolysis 22:521-525 ß 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins. Blood Coagulation and Fibrinolysis 2011, 22:521-525
Immune thrombocytopenia is an autoimmune disorder characterized by antibody-mediated platelet destruction. A protein tyrosine phosphatase (PTPN22) present in lymphocytes is an important negative regulator of signal transduction for the T-cell receptor-MHC complex and has been associated with autoimmune disorders that produce autoantibodies. The present study investigated the frequency of the 1858C>T single-nucleotide polymorphism (SNP) in the PTPN22 gene in idiopathic thrombocytopenic purpura (ITP) patients. This case series study included 50 children with ITP, 24 acute and 26 chronic cases, and 50 normal children as a control group. All were subjected to clinical history and laboratory investigations including complete blood count, genotyping of PTPN22 1858C/T SNP by polymerase chain reaction-restriction fragment length polymorphism and platelet antibodies using platelets suspension immunofluorescence test for the cases. Thirteen patients (26%) were positive for the PTPN22 1858C>T SNP. Three patients were homozygous for the mutation and 10 were heterozygous. Comparison of the 26% of the ITP patients who were positive for the PTPN22 1858C>T mutation with the 6% positive in the control group yielded a P value of 0.006. Antiplatelet antibodies were detected in five patients (20.8%) with acute ITP and in three patients (11.5%) with chronic ITP; no significant association between the presence of PTPN22 1858C>T mutation and the presence of antiplatelet antibodies was detected. The prevalence of PTPN22 gene mutation was higher in ITP patients, thus it may be considered as a genetic risk factor in the development of ITP in Egyptian children. 
Introduction
Idiopathic thrombocytopenic purpura (ITP) is an acquired organ-specific autoimmune hemorrhagic disease characterized by the production of autoantibodies that mediate platelet destruction [1] . Although auto-reactive B lymphocytes secreting antiplatelet antibodies are considered the primary immunologic defect in ITP, dysfunctional T-lymphocyte immunity plays an important role in the pathophysiology of ITP [2] . Direct T-cell-mediated cytotoxicity against megakaryocytes and platelets may be the primary mechanism in a proportion of patients [3] . Up-regulation of genes involved in cell-mediated cytotoxicity in CD3 þ and CD8 þ T cells from patients who had ITP had been reported to play a key role [4] .
Human PTPN22 gene is located on chromosome 1p13.3-13.1 and encodes an 807-amino acid residue protein referred to as lymphoid tyrosine phosphatase (LYP) [5] . This is an intracellular tyrosine phosphatase acting immediately downstream from the T-cell receptor and is a member of a family of proteins, involved in suppressing spontaneous T-cell activation and implicated in maintaining the resting phenotype of lymphocytes and controlling signals caused by an antigen co-stimulation and cytokines [6] .
A functional C-to-T single-nucleotide polymorphism (SNP) at position 1858(T1858) in the PTPN22 gene changes the amino acid residue 620 from Arg (R) to Trp (W) in the LYP protein resulting in a dominant gain-of-function mutant. This disease-predisposing allele (LYP W620) encodes for a significantly more active phosphatase [7] .
An association of PTPN22 (R620W) polymorphism was reported with many autoimmune diseases first with type 1 diabetes [8] and later also with rheumatoid arthritis (RA) [9] , juvenile rheumatoid arthritis (JRA) [10] , systemic lupus erythematosus (SLE) [11] , Graves' disease [12] , as well as generalized vitiligo [13] . These results provide compelling evidence that LYP is a critical player in multiple autoimmune disorders [14] . T-cell abnormalities are reported in ITP, but the relationship of these changes in T cells to the increased representation of the PTPN-22 polymorphism in ITP patients remains to be investigated [15] .
In this study, we analyzed the PTPN22 (R620W) polymorphism in Egyptian children with ITP, to evaluate the contribution of the C1858T SNP to ITP susceptibility.
Methods
The study included 50 ITP patients (24 acute and 26 chronic) attending the Paediatric Hematology outpatient clinic -Abu El Rish -Cairo University Hospital, as well as 50 age and sex-matched healthy (nonthrombocytopenic) children.
Patients with idiopathic thrombocytopenic purpura were diagnosed based on history taking, physical examination, and laboratory results including a complete blood count revealing isolated thrombocytopenia: platelet count (<100 Â 10 9 /l), normal hemoglobin concentration and white blood cell count. Additional inclusion criteria were: a marrow morphology, when obtained, compatible with the diagnosis of ITP; no concomitant autoimmune disorders; no medications known to cause thrombocytopenia; no associated viral disorders and no current diagnosis of malignancy. Exclusion criteria included infants below 6 months of age, recent manifestations of active infection, splenomegaly and secondary causes of ITP, such as systemic lupus erythematosus (SLE).
Our ITP patients were classified by duration into newly diagnosed (acute), persistent (3-12-month duration) and chronic cases (>12-month duration) [16] .
Blood samples for genotyping were obtained from 50 unrelated ITP patients and 50 controls for the PTPN22 C1858T polymorphism study, whereas antiplatelet antibody testing was performed for the ITP patients.
The study design was approved by the Scientific Research Committee of Pediatrics Department, Faculty of Medicine of Cairo University. Data confidentiality was preserved according to the Revised Helsinki Declaration of Bioethics [17] . All parents and/or surrogates were informed about the aims of the study. Formal written consents were obtained from the caregivers of the participants who agreed to their child's participation in the study.
Platelet antibody testing
Platelet antibodies were detected using platelets suspension immunofluorescence test (PSIFT) described by Von Dem Borne et al. [18] . Two drops (0.1 ml) of a suspension of paraformaldehyde (PFA)-fixed platelets obtained from blood group O donor were incubated with 0.1 ml of serum for 30 min at 378C. After incubation, the platelets were washed three times with ethylenediaminetetraacetic acid (EDTA)-phosphate buffered saline (PBS) and incubated with 0.1 ml of an fluorescein isothiocyanate (FITC)labeled antiglobulin for 30 min at room temperature.
The platelets were then washed twice and resuspended in glycerol-PBS (three parts glycerol to one part PBS). The platelets were mounted on a glass slide, covered with a cover slip and examined with a fluorescence microscope.
The PTPN22 C1858T polymorphism study
DNA extraction
Peripheral blood specimens were collected from all patients in vacuum tubes containing EDTA. Genomic DNA was extracted using AxyPrep Blood Genomic DNA Miniprep Kit (catalogue number AP-MN-BL-GDA-50; Axygen Biosciences Inc., Ocean City, California, USA) according to the manufacturer's instructions.
PTPN22 genotyping
The C1858T SNP within the coding region of the PTPN22 gene was analyzed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The primer sequences and restriction enzyme are given in The mutant 1858T allele cannot be digested and yielded one fragment of 218 bp, whereas the 1858C allele yielded two fragments of 176 and 46 bp ( Fig. 1 ).
Statistical analysis
The data were summarized using descriptive statistics: mean and standard deviation for quantitative variables and number and percentage for qualitative values.
Statistical differences between groups were tested using Chi-square test for qualitative variables while nonparametric Mann-Whitney test and Kruskal-Wallis test were used for nonquantitative variables, which were not normally distributed. Correlations were done to test for linear relations between variables. Values less than or equal to 0.05 were considered statistically significant. Odds ratios (ORs) and 95% confidence intervals (CIs) were used for estimating the relative risk for genotypes. The data were coded and entered using the statistical package SPSS version 15 (SPSS Inc., Chicago, Illinois, USA).
Results
The study included 50 patients suffering from ITP. Twenty-six (52%) of them fulfilled the criteria of chronic Antiplatelet antibodies were detected in five patients (20.8%) with acute ITP and three patients (11.5%) with chronic ITP, revealing no statistically significant difference (P > 0.05). Table 2 and Fig. 2 present the genotype frequency among patients and controls. Comparison of the 26% of the ITP patients who were positive for the PTPN22 1858C>T mutation with the 6% who were positive in the control group revealed a statistically significant difference (P ¼ 0.006). Also, a statistically significant difference was found regarding the frequency of the T/T and C/T genotypes among patients with both acute (P ¼ 0.011) and chronic ITP (P ¼ 0.05), compared to controls. However, no statistically significant difference was found regarding the frequency of these genotypes among patients with acute ITP compared to those with chronic ITP (P > 0.05). Table 3 and Fig. 3 present the frequency of the T and C alleles. A statistically highly significant difference was found between their frequency in ITP patients (16.0%), both acute (16.7%) and chronic (15.4%) groups, compared to controls (3%) (P < 0.05). No statistically significant difference was found regarding the frequencies of the T and C alleles among patients with acute ITP and those with chronic ITP (P > 0.05).
Logistic regression analysis among patients and controls was done to test for significant predictors for the presence of the T allele. A significant relation was found between
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By logistic regression analysis among patients with ITP, no statistically significant relation was found between age, sex, age at onset of the disease, platelet count, antiplatelet antibodies, acute versus chronic disease and the presence of the T allele (P > 0.05).
Discussion
Our study shows that analysis of the genotypes of Egyptian children with ITP (both acute and chronic) revealed its association with a higher frequency of the PTPN22 1858C/T SNP than in the healthy controls.
We found that 13 (26%) among our ITP patients were positive for the PTPN22 1858C>T SNP. Among these, 3 patients were homozygous (6%) for the mutation and 10 (20%) were heterozygous, compared to the three patients (6%) having this polymorphism in the control group which revealed a statistically significant difference (P ¼ 0.006) ( Table 2) .
We also found a highly statistically significant difference regarding the frequency of the T/T and C/T genotypes among patients with acute ITP compared to healthy controls (P ¼ 0.011) and a borderline significance between those with chronic ITP and controls (P ¼ 0.05). However, no significant difference was detected, regarding the frequency of these genotypes among patients with acute ITP compared to those with chronic ITP (P ¼ 0.624) ( Table 2 ), suggesting that additional factors may be responsible for the development of the chronic form of the disease.
In our study, the frequency of the T allele in children with ITP was 16.0%, 16.7% in acute and 15.4% in chronic ITP patients, respectively. These frequencies are statistically significant compared to controls (3%) (P ¼ 0.002, P ¼ 0.005 and 0.008, respectively) ( Table 3 ). These results agreed with the results by D'Silva et al. [19] who stated that the T-allele frequency in the ITP patients was 15.5% which was statistically different from the allele frequency of 8.7% observed in a population of 926 normal individuals (P ¼ 0.02); however, they found no statistically significant difference in the genotype frequency between the patient and the control group (P ¼ 0.08).
The percentage of ITP patients with the PTPN22 1858C>T mutation (26%) in our study is statistically similar to the citations for genotypic frequencies reported for RA, SLE, type 1 diabetes, and Graves' disease [8, 9, 11] . The fact that LYP W620 is associated with multiple autoimmune diseases may indicate that the altered function of LYP affects a pathway or mechanism shared among these diseases. Loss of central and/or peripheral tolerance or altered regulatory T-cell function would fit this notion. Presumably, the few autoimmune diseases that do not associate with LYP W620, that is multiple sclerosis (MS) and inflammatory bowel disease (IBD), are less dependent on the processes that are altered in the presence of LYP W620. Indeed, IBD appears to be intimately connected to the barrier function of the intestine and the local inflammatory defense mechanisms [20] .
As LYP W620 is a gain-of function variant, that is catalytically more active, it predisposes to autoimmune disease because it suppresses T-cell receptor (TCR) signaling more potently during thymic development, resulting in the survival of auto reactive T cells that would normally be deleted by negative selection in individuals with LYP W620/LYP R620 genotype. This would also explain why the disease-associated allele is dominant and not recessive [20] .
It was also demonstrated that the 1858T variant alters not only the function and character of the T-cell compartment, but also has a direct impact on B-cell function. The B cells from patients who carry this variant have a decreased ability to respond to stimulation via the B-cell receptors (BCRs) resulting in the escape of autoreactive B cells into the periphery. This could enhance the subsequent development of auto-antibodies and is notable in light of the fact that the diseases associated with this variant have the production of auto-antibodies as a common characteristic [7] .
Despite the assumed involvement of autoantibodies in the pathology of the autoimmune diseases, which exhibit 1858C>T mutation, we are surprised that, our study shows no statistically significant association between PTPN22 1858C>T and presence of antiplatelet antibodies (P > 0.05). This result may be attributed to the small sample size as well as to the degree of sensitivity of the technique that we used to detect antiplatelet antibodies. The use of a more sensitive method could have detected more patients with positive antiplatelet antibodies and in turn could have made it possible to detect an association with PTPN22 genotype.
As autoimmune diseases are complex genetic disorders, they have been linked to several chromosome regions in humans [21] .
The association of PTPN22 with so many human autoimmune diseases places this gene, together with MHC and CTLA4, in the exclusive company of general autoimmunity genes, that is the very few genes that predispose to numerous autoimmune diseases. Of these genes, the MHC locus (human leukocyte antigen variants) has by far the greatest impact, followed by PTPN22 and then CTLA4 susceptibility variants [22] .
In our study, no association was detected between the PTPN22 genotype and the age at onset of disease or the patients' platelet count.
We concluded that the PTPN22 1858 C>T allele is present in an increased percentage of ITP patients. Thus it might play an important role as a genetic risk factor in development of ITP in Egyptian children.
To our knowledge, this is a novel study; no other investigators studied PTPN22 gene mutation in Egyptian children diagnosed with ITP. However, due to financial limitations, the number of controls included in this study is limited. Therefore, these results must be verified by further studies with larger patient populations as well as with a larger control population, for further assessment of the relation between the presence of the PTPN22 polymorphism and the development of childhood ITP as well as its association with the presence of autoantibodies.
As PTPN22 is implicated in many prevalent autoimmune diseases (and perhaps even in transplant rejection), an anti-LYP drug that could reverse the negative effects of the W620 variant on TCR signaling would be of broad value for the treatment of multiple human conditions [23, 24] .
